Background A 49-year-old man presented to a rheumatology clinic with a 2-month history of low back pain. The pain seemed to be inflammatory in origin, with nocturnal occurrence and substantial early ...

October 16, 2006 — The European Commission has approved pregabalin capsules for the treatment of central neuropathic pain associated with spinal cord injury, stroke, and multiple sclerosis; and ...

May 15, 2006 — Health Canada has approved a 500-mg tablet formulation of saquinavir mesylate that significantly reduces the daily pill count for patients with HIV; the European Commission has approved ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the subcutaneous formulation of Celltrion USA’s Zymfentra as maintenance therapy for patients ...

Credit: Celltrion USA. Zymfentra is a subcutaneous formulation of Inflectra, a biosimilar to Remicade. Zymfentra is indicated as maintenance treatment only; all patients must complete an IV induction ...

Infliximab is a monoclonal antibody that is administered intravenously to treat patients with chronic inflammatory diseases including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, plaque ...

Remicade comes as a powder. A healthcare professional mixes the powder with liquid to form a solution, which they give as an intravenous (IV) infusion. (This is an injection into a vein given over ...

New York, New York--(Newsfile Corp. - April 2, 2024) - The product infliximab for injection, licensed by Kexing Biopharm, has recently experienced a wave of encouraging news regarding its ...

The European Medicines Agency (EMA) has backed the use of Celltrion Healthcare’s subcutaneous infliximab without initial intravenous loading doses. Securing the regulatory recommendation boosts ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Patients with ulcerative colitis treated with Remicade were more likely to not experience serious ...

Merck & Co. today said it has launched in the U.S. a biosimilar of Remicade ® (infliximab), the blockbuster immune-mediated inflammatory disorders treatment it markets outside the U.S., including ...

New York, New York--(Newsfile Corp. - April 2, 2024) - The product infliximab for injection, licensed by Kexing Biopharm, has recently experienced a wave of encouraging news regarding its ...